Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria

J Dtsch Dermatol Ges. 2018 Apr;16(4):477-478. doi: 10.1111/ddg.13481. Epub 2018 Mar 26.

Authors

Markus Magerl¹, Dorothea Terhorst¹, Martin Metz¹, Sabine Altrichter¹, Torsten Zuberbier¹, Marcus Maurer¹, Karl Christian Bergmann¹

Affiliation

¹ Allergie-Centrum-Charité, Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin.

PMID: 29578281
DOI: 10.1111/ddg.13481

No abstract available

Publication types

Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma / drug therapy
Chronic Disease
Drug Administration Schedule
Eosinophilia / drug therapy
Female
Forced Expiratory Volume / drug effects
Humans
Immune Complex Diseases / chemically induced
Treatment Outcome
Urticaria / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
mepolizumab